A two-drug treatment delayed lung tumors coming back in lab models; whether it does the same in people remains unclear. The study looked at lung cancer cells that survive the first wave of treatment. These surviving cells can help tumors stop responding to a drug. Researchers found that a protein called TROP2 increased as these cells formed. It also helped the cells stay alive. The team paired osimertinib, a drug that blocks cancer growth signals, with sacituzumab tirumotecan. The second drug carries cancer-killing medicine to cells with TROP2. Together, the drugs reduced the buildup of surviving cells and delayed tumor return. These findings came from lab models, not confirmed results in people. An ongoing phase 2 study, an early test in people, is testing this pair. It involves people with advanced lung cancer and a specific gene change. Early results show signs that the treatment works. But the supplied summary gives no patient count, response rate, or length of benefit. It also gives no side effect figures. For our eGFR (Estimated GFR) community, the similar names matter. EGFR in this cancer study refers to a protein involved in cell growth. It is not the kidney filtration estimate we track. This source reports no kidney filtration results and offers no evidence of improved kidney function. When comparing your bloodwork and notes with the community, keep that distinction clear. A matching set of letters does not mean a finding explains your numbers. What confusing test names have you come across while tracking your kidney results?